Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting

• Status: Unknown status
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in opioid-tolerant patients in the primary care outpatient setting.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Washington
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Age 18 years or older

• Routine use of an opioid medication for non-cancer pain for more than six months

• A current average daily dose of greater than or equal to 20 mg morphine or equivalent

• Current prescription of an as-needed opioid suitable for downward titration during the study period

• Ability to provide informed consent Ability to adhere to the study protocol

Exclusion Criteria:

• Uncontrolled hypertension, cardiac arrhythmia or other known cardiac disease,

• elevated intracranial pressure,

• severe glaucoma,

• schizophrenia,

• diagnosed substance use disorder, or

• other unstable medical or psychiatric illness or pregnancy.